News blog

Curidium Medica

  • BY: Andrew Hore |
  • POSTED: 05/12/2007 |

Personalised medicine developer Curidium Medica has signed a strategic partnership with Japanese pharma group Takeda.

Takeda, which is the 16th largest pharma company in sales terms, will pay £1.25m to finance research into sub groups of depression. This is the first external company to show faith in Curidium’s Homomatrix development technology, which helps to target medicines.

Longer-term, this could lead to Takeda negotiating a licence for the intellectual property. That could generate up-front and milestone payments as a treatment is developed, followed by royalties on any sales.

Curidium should have enough cash to finance at least two years development spending.

The shares rose 0.25p to 3.125p.

© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds